Press Releases Press Coverage Media Inquiries Get updates on drug lawsuits, settlements and PAL news.

Recent Press Releases Newly-Unsealed Documents Shed Light on Abbott Laboratories' 400% Norvir Price Hike   05/12/2008 PAL joins "friend of the Court" brief supporting new U.S. Patent Rules   12/20/2007 PAL Applauds Federal Court Damages Decision in AWP Case   11/02/2007 PAL & 26 organizations submit comments to FDA on drug ad study   10/19/2007 Judge Allows Zyprexa Class Action to Go Forward, Says Courts are “in the Strongest Position” to Protect Public from Fraudulent Drug Marketing   06/28/2007 MORE PRESS RELEASES » Recent Press Coverage Drug makers agree to $125M settlement Eleven pharmaceutical corporations have agreed to pay $125 million to settle allegations that they deliberately inflated average wholesale prices on Medicare Part B drugs.   03/13/2008 Price of Prescriptions Tough to Swallow We need to stop treating prescription drugs like shampoo and fabric softener," said Alex Sugerman-Brozan, the director of the Prescription Access Litigation Project. "These are not just consumer products, they're medical treatments."   03/26/2008 Bracing for a Showdown Average manufacturer price is dead, or is it? Two months after a Federal District Court Judge granted a temporary restraining order, preventing the Centers for Medicare and Medicaid Services from implementing the new generic drug reimbursement model for Medicaid, the future of the reimbursement plan remains up in the air. Still, while it is unclear how or when the case will be resolved, most pharmacy experts agree that pharmacists will continue to see tightening in prescription drug reimbursement.   02/11/2008 Diet drug debuting with big splash Yesterday, a consumer coalition, Prescription Access Litigation, criticized GSK for making the drug available over the counter because of its side effects, which the group said include diarrhea, oily stools and flatulence.   06/08/2007 Don't Swallow the Hype "But willpower questions aside, the side effects are often intolerable. Orlistat's requisite diet is low-fat because unabsorbed fat can result in frequent, greasy stools and diarrhea that may become uncontrollable. That's why part of the FDA's lack of concern for potential consumer abuse is that a user overdosing on Alli won't make the same mistake twice. But it's still bound to happen, which is one reason consumer watchdog Prescription Access Litigation just awarded Alli their infamous Bitter Pill Award ("With 'allies' like this, who needs enemas?" hoots PAL)."   06/13/2007 MORE PRESS COVERAGE »

Copyright © 2007 Prescription Access Litigation, a project of Community Catalyst, Inc. All Rights Reserved. Contact Us